Alison J. Uriel

Manchester, ENG, United Kingdom

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 18 publications

Progressive multifocal leukoencephalopathy associated with immune dysregulation.

Progressive multifocal leukoencephalopathy associated with immune dysregulation.

Journal: BMJ case reports

Published: April 10, 2026

Characterising Hepatitis D Virus in the UK From 2011 to 2021.

Characterising Hepatitis D Virus in the UK From 2011 to 2021.

Journal: Journal of viral hepatitis

Published: March 20, 2026

Time to HIV rebound after antiretroviral therapy interruption: a double-blind randomised placebo-controlled trial of long-acting broadly neutralising antibodies; The RIO Trial.

Time to HIV rebound after antiretroviral therapy interruption: a double-blind randomised placebo-controlled trial of long-acting broadly neutralising antibodies; The RIO Trial.

Journal: medRxiv : the preprint server for health sciences

Published: February 12, 2026

T cell immunity predicts clinical outcomes on stopping antiretroviral treatment after HIV-specific broadly neutralising antibody therapy.

T cell immunity predicts clinical outcomes on stopping antiretroviral treatment after HIV-specific broadly neutralising antibody therapy.

Journal: medRxiv : the preprint server for health sciences

Published: February 12, 2026

Time to HIV rebound after infusion of long-acting broadly neutralising antibodies 3BNC117-LS and 10-1074-LS and analytical treatment interruption (the RIO trial): a double-blind, randomised, placebo-controlled trial.

Time to HIV rebound after infusion of long-acting broadly neutralising antibodies 3BNC117-LS and 10-1074-LS and analytical treatment interruption (the RIO trial): a double-blind, randomised, placebo-controlled trial.

Journal: The lancet. HIV

Published: December 09, 2025

Enhanced HIV-1 Control After Antibody Therapy is Associated with Autologous Antibodies and Reservoir Clearance in the RIO trial.

Enhanced HIV-1 Control After Antibody Therapy is Associated with Autologous Antibodies and Reservoir Clearance in the RIO trial.

Journal: medRxiv : the preprint server for health sciences

Published: November 24, 2025

Missed opportunities to prevent HIV acquisition with pre-exposure prophylaxis: A mixed methods study of people with recently acquired HIV in the United Kingdom.

Missed opportunities to prevent HIV acquisition with pre-exposure prophylaxis: A mixed methods study of people with recently acquired HIV in the United Kingdom.

Journal: HIV medicine

Published: July 11, 2025

Bictegravir/emtricitabine/tenofovir alafenamide in clinical practice for people with HIV: final 24-month effectiveness and safety outcomes in key populations in the observational BICSTaR cohort.

Bictegravir/emtricitabine/tenofovir alafenamide in clinical practice for people with HIV: final 24-month effectiveness and safety outcomes in key populations in the observational BICSTaR cohort.

Journal: HIV research & clinical practice

Published: February 12, 2025

Risk of severe bacterial infections including TB before and after immediate or deferred antiretroviral therapy: A multicenter, prospective, cohort study.

Risk of severe bacterial infections including TB before and after immediate or deferred antiretroviral therapy: A multicenter, prospective, cohort study.

Journal: International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases

Published: January 14, 2025

Safety and biologic activity of a bispecific T cell receptor targeting HIV Gag in males living with HIV: a first-in-human trial.

Safety and biologic activity of a bispecific T cell receptor targeting HIV Gag in males living with HIV: a first-in-human trial.

Journal: Nature communications

Published: December 13, 2024

Efficacy and safety of sipavibart for prevention of COVID-19 in individuals who are immunocompromised (SUPERNOVA): a randomised, controlled, double-blind, phase 3 trial.

Efficacy and safety of sipavibart for prevention of COVID-19 in individuals who are immunocompromised (SUPERNOVA): a randomised, controlled, double-blind, phase 3 trial.

Journal: The Lancet. Infectious diseases

Published: October 01, 2024

AZD3152 neutralizes SARS-CoV-2 historical and contemporary variants and is protective in hamsters and well tolerated in adults.

AZD3152 neutralizes SARS-CoV-2 historical and contemporary variants and is protective in hamsters and well tolerated in adults.

Journal: Science translational medicine

Published: June 26, 2024

Showing 1-12 of 18

Last Updated: 09/26/2026